Telix’s new investigational prostate cancer imaging product is intended to address the unmet needs of patients, ..... and expand patient reach using Telix’s established nuclear pharmacy distribution partnerships and industry-leading on-time reliability
so, its an additional product to meet unmet needs
and
there was discussion of Illuccix 2.0, but we didn't have these details on the new product.
I don't believe it will replace existing Illuccix, but it does have some attributes, apparently, to serve the unmet market needs
Ann: Telix Submits NDA for New Prostate Cancer Imaging Agent, page-13
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.65 |
Change
0.250(1.36%) |
Mkt cap ! $6.233B | |||
| Open | High | Low | Value | Volume |
| $18.56 | $18.81 | $18.43 | $49.28M | 2.643M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4262 | $18.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.68 | 1840 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| TLX (ASX) Chart |